The trial is designed to assess the tolerability, efficacy, and safety of two different dosages of the therapy.

Oculis Holding ( (OCS) ) has issued an update. Oculis Holding has announced positive results from a Phase 2 trial for OCS-05, a potential first-in-class neuroprotective therapy for acute optic ...

By Karen Roman Oculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of ...

BofA raised the firm’s price target on Oculis (OCS) to $31 from $23 and keeps a Buy rating on the shares. The company reported Phase 2 results ...

Oculis (NASDAQ:OCS – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to ...

When the body’s immune system reacts to an infection like HMPV, it can sometimes overreact, causing inflammation not only in ...

Pacira receives FDA approval for a new iovera Smart Tip aimed at expanding pain management capabilities to deeper nerves like ...

Shares of Oculis Holding AG (NASDAQ:OCS – Get Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $18.10 and last traded at $17.57, with a volume of ...

OCS-05 was well tolerated and improved vision and eye health in a Phase 2 trial in 33 people with optic neuritis due to MS or ...

OCS-05 met safety and efficacy endpoints in the treatment of acute optic neuritis in a phase 2 trial, according to a press release from Oculis. Inappropriate use of medication for insomnia was ...

HMPV, also known as Human Metapneumovirus, is a virus that causes symptoms similar to cold. Cases of HMPV have been detected ...